ACIU AC Immune SA

5.79
0  0%
Previous Close 5.79
Open
Price To Book 1.62
Market Cap 391,185,908
Shares 67,562,333
Volume 0
Short Ratio
Av. Daily Volume 191,193

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 2
Alzheimer’s disease
Phase 2 data due 2020.
RG6100 (Anti-Tau RO7105705)
Alzheimer’s disease
Phase 1/2 interim high dose cohort data due 1H 2019, low dose cohort data due 2019.
ACI-24 (anti-Abeta vaccine)
Alzheimer's disease-like characteristics in individuals with Down syndrome
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 1
Alzheimer’s disease
Phase 2 trial initiation announced August 20, 2018.
ACI-24
Alzheimer’s disease
Phase 2 trial initiation announced February 20, 2019.
MTAU9937A
Alzheimer’s disease
Phase 2 trial planned for 1H 2019.
ACI-35
Alzheimer’s disease

Latest News

  1. AC Immune Reports Initiation of a Phase 2 Substudy to Increase Understanding of Disease Progression in Familial Alzheimer’s Disease
  2. AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates
  3. AC Immune: 1Q Earnings Snapshot
  4. AC Immune Reports Q1 2019 Financial Results and Business Update
  5. Here’s What Hedge Funds Think About AC Immune SA (ACIU)
  6. AC Immune (ACIU) to Report Q1 Results: Wall Street Expects Earnings Growth
  7. What Percentage Of AC Immune SA (NASDAQ:ACIU) Shares Do Insiders Own?
  8. Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003
  9. AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference
  10. AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PD™ Conference
  11. Lilly (LLY) Signs New Immunology Deal With Private Biotech
  12. New Clinical Data on AC Immune’s Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD™ Conference
  13. What Makes AC Immune (ACIU) a New Buy Stock
  14. AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update
  15. AC Immune to Report Progress of Early-Stage Pipeline at AD/PD™ Congress
  16. Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?
  17. Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?
  18. What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?
  19. AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer’s Disease
  20. AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development